<DOC>
	<DOCNO>NCT02075697</DOCNO>
	<brief_summary>The purpose Biobadaderm study safety systemic therapy psoriasis .</brief_summary>
	<brief_title>Spanish Registry Systemic Treatments Psoriasis</brief_title>
	<detailed_description>The Spanish Registry Adverse Events Biological Therapies Dermatology ( BIOBADADERM ) launch October 2008 , pharmacovigilance effort psoriatic patient . The registry manage Foundation Spanish Academy Dermatology Venereology ( AEDV ) . BIOBADADERM promote AEDV , collaboration Spanish Agency Medicines Health Products ( AEMPS ) Research Unit Spanish Foundation Rheumatology ( FER ) Research Unit Fundacion AEDV . BIOBADADERM part PSONET , European network share data record patient treat biologics . BIOBADADERM prospective cohort patient receive biologic drug compare another cohort patient receive systemic treatment . One cohort make consecutive psoriasis patient begin biological therapy ( include infliximab ( INF ) , etanercept ( ET ) , efalizumab ( EFA ) , adalimumab ( ADA ) , rituximab ( RTX ) ustekinumab ( UTK ) ) centre . The control cohort consist psoriasis patient begin , first time , nonbiologic systemic treatment ( methotrexate , cyclosporine acitretin ) . The objective BIOBADADERM : - Identify adverse event ( AEs ) occur relevant treatment biologic therapy , estimate frequency ; - Identify unexpected AEs , particularly may occur long period exposure ; - Identify relevant AEs arise discontinuation treatment ; - Estimate relative risk develop AEs biologic therapy patient psoriasis compare psoriatic patient expose systemic ( non-biological ) ; - Identify risk factor AEs patient treatment . Data initially collect retrospectively hospital list patient receive biologic drug 1 January 2005 30 October 2008 check-ups frequency least every 6 month . Since 2008 , data capture prospectively . The database include demographic , diagnostic comorbidity data , treatment perform , duration treatment adverse effect arise ( cod use MedDRA ) . In first year , 632 patient 12 center participate BIOBADADERM . In October 2012 registry data 1,793 patient , include 946 patient biologic treatment 847 patient non-biologic systemic treatment . Data patient reversibly anonymized entered database . Data enter Internet ( http : //biobadaser.ser.es/biobadaderm/ ) . The data store Research Department Spanish Rheumatology Foundation . The included data continually revise online study monitor verify consistency , comprehensiveness , absence anomaly . A follow-up visit make every year sample data database compare clinical record . Sample size calculate give , 5 year , 80 % power use alfa level= 0.05 , detect rate ratio 2 event 4.1 case per 1000 person-years , rate ratio 5 event 0.5 case per 1000 person-years . Further calculation available study protocol ( http : //biobadaser.ser.es/biobadaderm/index.html ) . Default value variable `` miss '' . Plans miss data analysis depend aim analysis preference conservative ( term patient safety ) analysis . Analysis consist description rate , rate ratio adjust rate ratio ( adjust possible confounders , age always include ) .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>For biologics group : consecutive psoriasis patient begin biological therapy For classic systemic group : next psoriasis patient begin , first time , nonbiologic systemic treatment ( include patient biologics group ) Intention move different geographic area next three month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>biologic therapy</keyword>
	<keyword>infliximab</keyword>
	<keyword>etanercept</keyword>
	<keyword>efalizumab</keyword>
	<keyword>adalimumab</keyword>
	<keyword>ustekinumab</keyword>
	<keyword>methotrexate</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>acitretin</keyword>
</DOC>